Details : VIC-1911 is a novel, highly selective, and orally active small molecular inhibitor of aurora kinase A (AURKA). AURKA gene amplification/overexpression is reported in multiple tumors, including NSCLC.
Brand Name : VIC-1911
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2023
Lead Product(s) : VIC-1911,Cyclophosphamide,Sirolimus
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : University of Minnesota Medical School
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VIC-1911 is a novel and orally active inhibitor of Aurora A kinase, a key regulator in mitotic cell division and sirolimus specifically designed to substantially reduce GVHD, facilitate full potential of leukemia effect, and maximize GVHD-free, relapse-f...
Brand Name : VIC-1911
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2022
Lead Product(s) : VIC-1911,Cyclophosphamide,Sirolimus
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Minnesota Medical School
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Two Phase-1 clinical studies have been conducted in the US and Europe by Taiho. VITRAC obtained an exclusive and global development and commercialization rights for TAS-119, and its IND has been successfully transferred to VITRAC in the US with a new cod...
Brand Name : VIC-1911
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
June 29, 2020
LOOKING FOR A SUPPLIER?
Reset All
